Experienced in Developmental Dysphasia Familial

Yan H. Bi

No 321, Zhongshan Road, 
Nanjing, CN 
Experienced in Developmental Dysphasia Familial
No 321, Zhongshan Road, 
Nanjing, CN 
OverviewLocationsClinical Research

Overview

Yan Bi practices in Nanjing, China. Mr. Bi is rated as an Experienced expert by MediFind in the treatment of Developmental Dysphasia Familial. His top areas of expertise are Type 2 Diabetes (T2D), Non-Alcoholic Fatty Liver Disease, Obesity, Gastric Bypass, and Endoscopy.

His clinical research consists of co-authoring 343 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Developmental Dysphasia Familial.

Gender
Male

Locations

No 321, Zhongshan Road, Nanjing, 210008, China
Other Locations
321 Zhongshan Street, Nanjing, 210008, China
No. 321 Zhongshan Rd, Nanjing, 210008, China
No 321 Zhongshan Road, Nanjing, China
320 Yueyang Road, Yueyang, 200031, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Investigator-initiated, Prospective, Randomized, Open Label, Parallel Study to Explore and Evaluate the Therapeutic Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairment.
An Investigator-initiated, Prospective, Randomized, Open Label, Parallel Study to Explore and Evaluate the Therapeutic Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in T2DM Patients With Mild Cognitive Impairment.
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Not Applicable
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients
The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients
Enrollment Status: Completed
Publish Date: May 30, 2019
Intervention Type: Other, Behavioral, Procedure
View 3 Less Clinical Trials

343 Total Publications

Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
Journal: Diabetes, obesity & metabolism
Published: September 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bi's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile